Meeting
2022 ASCO Annual Meeting
CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer.
Presenter
Thomas Powles, MD, PhD, FCRP
Barts ECMC, Barts Cancer Institute, Queen Mary University of London
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02819596
Citation
J Clin Oncol 40, 2022 (suppl 17; abstr LBA4503)
DOI
10.1200/JCO.2022.40.17_suppl.LBA4503
Abstract #
LBA4503
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2019 Genitourinary Cancers Symposium
A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).
Speaker: Thomas Powles, MD, PhD, FCRP
Videos & Slides
2019 Gastrointestinal Cancers Symposium
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
Speaker: Eric Xueyu Chen, MD, PhD
Speaker: Suzanne Louise Topalian, MD
Videos & Slides
2024 ASCO Annual Meeting
Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
Speaker: Carlos Rojas, MD